Last updated: July 22, 2026
Exeltis USA, Inc. v. Lupin Ltd. (1:24-cv-00732): Litigation Summary, Patent Claims, and Generic Entry Impact
Exeltis USA, Inc. v. Lupin Ltd., No. 1:24-cv-00732, is a 2024 U.S. patent infringement case tied to a Paragraph IV pathway dispute. The litigation posture and likely generic entry risk depend on (i) which Orange Book patents are asserted and (ii) whether the action is tied to an ANDA approval date, a settlement, or a dismissal/consent judgment. Without the docket record and asserted-patent set, a complete, accurate litigation summary cannot be produced.
What patents are asserted in Exeltis USA, Inc. v. Lupin Ltd. (1:24-cv-00732)?
No asserted-patent numbers, claims, or patent titles are available in the provided input. A litigation summary for this case requires the complaint’s asserted list, the specific claim(s) in suit, and whether the pleading includes multiple Orange Book listed patents (drug substance, formulation, method of use, and/or manufacturing).
Which Orange Book patent categories typically drive cases like this?
- Drug substance/process patents
- Drug product/formulation patents
- Method-of-use (treatment/dosing) patents
- Combination-of-actives patents (if relevant)
- Manufacturing-method patents (less common but seen)
What is the procedural timeline for 1:24-cv-00732 (complaint, motions, claim construction, trial)?
The procedural timeline cannot be stated from the provided input. A credible litigation analysis requires docket events such as:
- complaint filing date and venue assignment
- answer and invalidity/ non-infringement defenses
- any Rule 12 motion outcomes
- scheduling order, Markman (claim construction) dates
- expert disclosures and dispositive motions
- settlement conference entries
- trial scheduling or dismissal/consent judgment entries
Who are the parties and what roles do they play in this Paragraph IV dispute?
The input identifies only the parties’ names and the case number. A litigation-grade analysis requires:
- plaintiff’s asserted rights holder(s) and real party in interest
- Lupin’s accused product(s) and dosage form(s)
- whether Exeltis is acting as NDA holder, Orange Book holder, or assignee
- whether any co-defendants are present (often yes in ANDA cases)
What is the Orange Book status of Exeltis’s product at issue in 1:24-cv-00732?
Orange Book listing status cannot be provided from the input. Litigation outcomes and launch timing are driven by:
- which listed patents are “active” vs expired
- the listed expiration dates (including pediatric exclusivity impact where applicable)
- whether additional patents are listed after the NDA approval date
- whether the case covers one patent or multiple patents
When does generic entry become legally possible after Exeltis v. Lupin?
The generic launch window depends on:
- the latest expiration among asserted patents
- whether a court enters a final judgment of invalidity/non-infringement
- whether an infringement finding triggers statutory forfeiture
- whether a settlement includes an agreed launch date or “design-around” scope
Without asserted-patent expiration dates and docket dispositions, no accurate entry timing can be stated.
What is the strength of the patent estate asserted by Exeltis (validity, enforceability, and infringement)?
A strength assessment requires:
- the claim language at issue
- file history, prior art record, and obviousness posture
- the court’s Markman rulings, claim construction outcomes
- summary judgment decisions (if any)
- any final validity determinations
No such records are provided.
Has Lupin filed a Paragraph IV certification, and what is the litigation’s impact on ANDA approval?
The presence of a Paragraph IV certification is typical for this case type, but the record is not included. A proper analysis requires:
- which certification(s) are at issue (IV vs I/II/III)
- whether the case is tied to FDA approval timing or a “sole” approval event
- whether the FDA paused approval due to the 30-month stay or subsequent injunction
What is the settlement status in Exeltis USA, Inc. v. Lupin Ltd., and did it create a launch carve-out?
Settlement terms cannot be assessed without:
- docket entries indicating settlement
- a consent judgment or stipulated dismissal
- any publicly filed agreement or court-approved settlement document
- whether the settlement includes a delayed launch date, an exclusivity forfeiture, or design-around constraints
How does this litigation compare with other Exeltis patent cases against generics filed around 2024?
Comparison requires access to other case dockets, asserted patents, and outcomes. The input does not include comparator case numbers, product names, or targets.
Where can this case be enforced geographically (U.S.-only enforcement vs global IP strategy)?
Patent infringement actions here are U.S.-jurisdictional. Business impact can extend to:
- other country filings
- manufacturing relocation constraints
- regulatory exclusivity positions
- distribution agreements conditioned on U.S. outcomes
But enforcement scope cannot be tied to 1:24-cv-00732 without product identity and any related licensing strategy.
Key Takeaways
- A litigation-grade summary for Exeltis USA, Inc. v. Lupin Ltd. (1:24-cv-00732) requires the docket record and asserted-patent set (complaint, scheduling orders, Markman rulings, and final disposition).
- The input does not include asserted patents, procedural milestones, or outcomes, so no accurate expiration-driven entry timing, validity analysis, or settlement impact can be stated.
FAQs
- What information from the docket determines whether Lupin’s ANDA launch is blocked in 1:24-cv-00732?
- How do asserted formulation vs method-of-use patents typically change “design-around” options for ANDA challengers?
- What docket milestones usually signal a Markman ruling that can shift infringement/validity odds in ANDA cases?
- How do court outcomes (infringement findings vs invalidity rulings) translate to statutory patent expiration enforcement?
- What settlement structures are most common in Paragraph IV cases involving delayed launch or carve-outs?
References
- Not available from the provided input.
